Sex and the (Not Quite) Single Arthritis Patient
COPENHAGEN — Half of patients with rheumatoid arthritis (RA) and 30% of those with psoriatic arthritis (PsA) reported substantial problems with sexual function, according to a survey reported here. Among 27 with RA diagnoses, 13 had scores on the 14-item Changes in Sexual Functioning Questionnaire (CSFQ) in the range indicative of sexual dysfunction, said Carlos […]
Year in Review: Psoriatic Arthritis
The year 2021 saw additional advances and refinements in the treatment of psoriatic arthritis (PsA), a heterogeneous condition that in the past has lagged behind rheumatoid arthritis (RA) in therapeutic progress. But improved understanding of the pathogenesis of PsA has allowed more targeted, safer, and more effective treatment approaches. In particular, data have begun to […]
Brepocitinib Shows Promise in Phase II Trial for PsA
The oral tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib showed efficacy for psoriatic arthritis (PsA) in a phase IIb trial. At week 16, a 20% improvement on the criteria of the American College of Rheumatology (ACR20) was observed in 66.7% of patients receiving 30 mg brepocitinib daily as did 74.6% of those given 60 mg […]
Targeting IL-23 Succeeds in Psoriatic Arthritis
The monoclonal antibody risankizumab (Skyrizi) showed significant efficacy for psoriatic arthritis (PsA) in two phase III randomized trials, a researcher reported. In the KEEPSAKE 1 and 2 trials, 1,407 patients with active PsA were randomly assigned to receive subcutaneous risankizumab, 150 mg, or placebo at baseline and then at weeks 4 and 16. On the […]